AUVELITY is a Oral Tablet, Multilayer, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Axsome Therapeutics, Inc.. The primary component is Bupropion Hydrochloride; Dextromethorphan Hydrobromide.
| Product ID | 81968-045_2a8f1d11-4605-4bde-906f-e99165721141 | 
| NDC | 81968-045 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | AUVELITY | 
| Generic Name | Dextromethorphan Hydrobromide, Bupropion Hydrochloride | 
| Dosage Form | Tablet, Multilayer, Extended Release | 
| Route of Administration | ORAL | 
| Marketing Start Date | 2022-08-18 | 
| Marketing Category | NDA / | 
| Application Number | NDA215430 | 
| Labeler Name | Axsome Therapeutics, Inc. | 
| Substance Name | BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE | 
| Active Ingredient Strength | 105 mg/1; mg/1 | 
| Pharm Classes | Aminoketone [EPC], Dopamine Uptake Inhibitors [MoA], Increased Dopamine Activity [PE], Increased Norepinephrine Activity [PE], Norepinephrine Uptake Inhibitors [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2023-12-31 | 
| Marketing Start Date | 2022-08-18 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  AUVELITY  90450929  not registered Live/Pending | Axsome Therapeutics, Inc. 2021-01-06 |